SLC5A2 and type 2 diabetes mellitus: Nevertheless, it must be remembered that patients with HFpEF often presentseveral comorbidities, aside from type 2 diabetes, which may broaden thepopulation eligible for SGLT2 inhibition according to strict trial criteria.